

Antituberculosis and Toxicity Assay of ethanolic extract of Mimba Cortex (*Azadirachta indica* JUSS.)

Cut Fatimah^{1*}, ErfanWahyudi¹, and Ernawati B²

¹Universitas Tjut Nyak Dhien, Medan, Sumatera Utara, Indonesia

²Local Health Laboratory, Sumatera Utara, Indonesia

Abstract

According to WHO has identified so much people with tuberculosis disorder, and includes a disease that causes death. *Mycobacterium tuberculosis* has been resistant to antituberculosis drugs were used, while the discovery of new synthetic antituberculosis are very slow. Traditionally, mimba cortex has been used to treat cough and bloody sputum. In previous research proved that the ethanol extract of mimba cortex can inhibit the *in vitro* growth of *Mycobacterium tuberculosis*. This study was conducted to determine the potential of mimba cortex as antituberculosis *in vivo* and toxicity test. Antituberculosis potency test *in vivo* in guinea pigs infected with *Mycobacterium tuberculosis* H37Rv directly into the bronchi using nebulizer. Then given mimba cortex extract 3 times a day 100 mg/kgBW and 50 mg/kgBW. Isoniazid, Rifampicin and Ethambutol used as a comparison. Antituberculosis assessment examination conducted by *Mycobacterium tuberculosis* on bronchial fluid specimens were taken every two weeks and tested in culture with Lowenstein-Jensen method. Acute toxicity test conducted on mice, the LD₅₀ value calculation and observation of liver, kidney, and lung histopathology. The result of research showed that the ethanol extract of mimba cortex have antituberculosis activity in guinea pigs which has infected with *Mycobacterium tuberculosis* H37Rv, 3 times daily dosing of 100 mg/kgBW for 6 weeks, showed that bacterium from +3 to negative, and 3 times daily dosing of 50mg/kgBW showed that bacterium from +3 to +1. Acute toxicity test results showed LD₅₀ 11.85 ± 0.571. That is including mild toxic category.

Keywords : mimba cortex, antituberculosis activity, acute toxicity

INTRODUCTION

Tuberculosis (TB) is the infectious disease caused by the *Mycobacterium tuberculosis* which infect both latently or progressively and transmitted by human through cough and respiration mechanism. *Mycobacterium tuberculosis* is the acid resistant bacteria which have the specific characteristic such as slow-rate growing but easily to become resistant. The slow-rate growing character for this bacteria is one of the factor causing the development of antituberculosis is more difficult than the other antibacteria (Ganiswara, 1995).

Tuberculosis is the threat for Indonesia society. In 2004, there were increase in the new cases of tuberculosis as many as 250,000 cases, and 140,000 death each year. Most of the tuberculosis patient are the productive age group aged 15-55 years old. This disease is the third deathly disease after cardiovascular disease and accute respirational disease in all age (Depkes RI, 2005).

The increase of the tuberculosis patient number is caused by some factors one of them is the uncompliance in the drugs therapy by the

patient. The other factors are the high price of the drugs, multiple drug resistance, lack of hospes immunity against micobacteria, reduction in bactericidal power of the drugs, and patient economy crisis (Depkes RI, 2005).

The drugs commonly used in the tuberculosis therapy are isoniazid, pirazinamid, rifampisin, ethambutol, and streptomycin. Most of the tuberculosis patient could be cure by those drugs, but the resistance phenomenon makes another choice for drugs therapy is needed (Wattimena, *et al.*, 1991).

Traditionally, mimba herbs (*Azadirachta indica* Juss) is used as the cure for some diseases, such as pertussis and cough up blood (Dalimata, 1999). Numerous studies have reported that mimba seeds can inhibit the growth of *Salmonella thyposa*, *Streptococcus aureus* (Ambarwati, 2007), *Streptococcus mutant* and *Streptococcus faecalis* (Almas, 1999).

*Corresponding author e-mail: cutmah57@gmail.com

Mimba oils can also inhibit the growth of *E. coli* and *Klebsiella pneumonia* (Sai Ram, et al., 2000) besides, the etanolic extract of mimbacortex can inhibit the growth of *Mycobacterium tuberculosis* (Fatimah, 2012).

Based on its empirical use property and the previous studies, mimba herbs have the potency as a natural antituberculosis agent. In this study, we determined the antituberculosis activity of ethanolic extract of mimba cortex (EEM) by *in vivo* assay using *Mycobacterium tuberculosis* H37RV infected marmot, and its toxicity using mice. The result of this research showed that mimba cortex potential to be developed as the alternative drugs of tuberculosis treatment.

MATERIALS AND METHODS

Plants Extraction

Mimba cortex was dried and powdered, then phytochemistry screening and quality test of simplisia was done. Extraction by percolation then conducted using 80% ethanol.

Antituberculosis Activity Assay

Antituberculosis activity of ethanolic extract of mimba cortex was determined using infected marmot. Marmot was spread using 3 mL suspension of *Mycobacterium tuberculosis* H37RV (from CV. Varka Bayak Medan) directly on bronchus by using nebulizer every 24 hours during 7 days respectively, continued with once every 2 days during 7 days and once every 3 days during 7 days. The spread of 20 mL aquadest was taken from esophagus. Identification and cultivation of *Mycobacterium tuberculosis* was done on LJ medium. The positive tuberculosis marmot then divided in 5 groups. Group 1: EEM 100 mg/kg BW, three times a day. Group 2: EEM 50 mg/kg BW, three times a day. Group 3: isoniazid control. Group 4: etambutol control. Group 5: rifampisin control. After administrated with each treatment, specimen sampling was done each week for 4-5 samplings. Specimens were placed in test tube then homogenized with phosphate buffer pH 7 and inoculated into two test tubes contain with LJ medium. Inoculums were incubated in 37°C for 6-8 weeks and the growth were observed with criteria:

- (-) : no growth
- (+1) : medium covered with slight colony, 1 – 200 colonies
- (+2) : ½ of medium surface covered with yellow colony, 200 – 500 colonies
- (+3) : ¾ of medium surface covered with yellow colony, 500 – 2000 colonies

- (+4) : all of medium surface covered with yellow colony >2000 colonies (Japan International Cooperation Agency, 1987).

Toxicity Assay

EEM was suspended in CMC-Na solution within 50% concentration. Toxicology assay was performed on 30 male mice (2-3 months), weighed from 20-30 grams, and were acclimatized for 7 days. Mice were divided 5 each treatments (WHO, 1993). Control treatment: CMC-Na control; treatment 1: EEM dose I; treatment 2: EEM dose II; treatment 3: EEM dose III; treatment 4: EEM dose IV and treatment 5: EEM dose V.

Toxicity assay was conducted in 3 stage of dose determination: dose orientation test, preliminary test, and actual test. LD₅₀ was determined using Thompson Weil method in multilevel dose consists of 5 doses variant. Physical observation of toxic symptom was conducted intensively during 24 hours to all groups of mice. Observation was continued within 14 days. The number of dead mice in each group was scored then the LD₅₀ range was determined according to the following formula:

$$LD_{50} \text{ range} = \text{antilog} (\text{Log } m \pm 2 \times \delta \text{ log } m)$$

Annotation:

m = LD₅₀

D = smallest dose

d = multiple dose log

f = Weil factor

Liver, kidney and lung was removed then immediately washed by aquadest and soaked in formaline buffer 10% to perform the histopatology assay.

RESULTS AND DISCUSSIONS

The Antituberculosis Activity of EEM

Antituberculosis activity assay was performed to 5 groups as explained in method section. The result indicates that there is an inhibition of bacterium growth. The number of bacterium before treatment is +3 (based on Japan International Cooperation Agency criteria). There is reduction from +3 to TB negative in control group at the third week of specimen sampling. The reduction of bacterium number from +3 to negative TB in group 1 occurs at the fourth week of specimen sampling.

Group 2 shows the reduction of bacterium number from +3 to +1 at the fourth week of specimen sampling.

EEM Toxicity Assay

First stage of test performed as orientation test to determine the dose administrated to the next stage of test. Mice were administrated with two multiple dose escalation of EEM and then observed during 24 hours until there is a death of mice. The result of this first test shows 20% death of group 4 which administrated with EEM dose 80 mg/20 g BW.

According to this orientation test result, preliminary test can be continued using the smallest dose of the orientation test. The preliminary test was conducted using EEM dose 50 mg/20 g BW, the dose approaching 20% death dose, because there was no death after 40 mg/20 g BW dose administration. Dose then increased to be 100 mg/20 g BW then observed during 24 hours. The result shows 0% death of group 1 and group 2. Based on the result, the actual test can be continued using the dose caused 0% death, 100 mg/20 g BW.

The assay then continued with minimal dose 100 mg/20 g BW. The dose multiplication were increased based on the calculation below:

$$R = 1.4142$$

$$R = \text{antilog } d$$

$$d = \frac{\log \text{dose multiplication}}{\text{total animal number of group 1}}$$

The calculation for dose multiplication between the groups and group 4 is 4, thus:

$$d = \frac{\log 4}{4}$$

$$d = \frac{0.602}{4} = 0.15051$$

$$R = \text{antilog } 0.15051 = 1.4142$$

The treatment were done for 14 days. Based on the assay, some male mice were dead by the single dose treatment in several dose of treatment. The LD₅₀ value were calculated with

Thompson well equation and the LD₅₀ value is 11.85 mg/kg BW per oral. The equation is stated below:

$$\text{Log } m = \text{Log } D + d (f + 1)$$

$$D = 141.42$$

$$d = 0.15051$$

$$f = \text{based on Weil table}$$

$$r = 1,3,3,2 \text{ is } = 0.50000$$

$$\text{Log } m = \text{Log } D + d (f + 1)$$

$$\text{Log } m = \text{Log } 141.42 + 0.15051 (0.50000 + 1)$$

$$\text{Log } m = 2.1505 + 0.15051 (1.50000)$$

$$\text{Log } m = 2.1505 + 0.2252$$

$$\text{Log } m = 2.3757 \text{ mg/20 g BB}$$

$$m = \text{antilog } 2.3757 = 237.54 \text{ mg/20 g BB}$$

$$\text{LD}_{50} = 0.237 \text{ g/20 g BB}$$

$$\text{LD}_{50} = 11.85 \text{ g/ kg BB}$$

Then the LD₅₀ range value was calculated. The LD₅₀ range value is (11.85 ± 0.571) mg/kg BW.

$$\text{LD}_{50} \text{ range value} = \text{antilog} (\log m \pm 2 \times \delta \log m)$$

$$\delta f = \text{based on Weil table}$$

$$r = 1,3,3,2 = 1.90394$$

$$d = 0.150151$$

$$m = \text{LD}_{50} \text{ value} = 0.237 \text{ g/20 g BW}$$

$$\delta \log m = 0.150151 \times 1.90394$$

$$\delta \log m = 0.28587$$

$$\text{LD}_{50} \text{ range value} = \text{antilog} (\log m \pm 2 \times \delta \log m)$$

$$= 0.237 \pm 2 \times 0.28587$$

$$= (0.237 \pm 0.57175) \text{g/20 g BW}$$

$$= (11.85 \pm 0.57) \text{g/ kg BW}$$

Based on the LD₅₀ range values shows that EEM classified in slightly toxic. The toxicity criteria of EEM single dose was determined using Frank C. Lu, (1995) criteria according to the following table:

Table 1. Toxicity criteria based on the LD₅₀ range values

Criteria	LD ₅₀ range values
Super toxic	≤ 5 mg/kgBB
Highly toxic	5–50 mg/kgBB
Very toxic	50-500 mg/kgBB
Moderately toxic	0.5 – 5 g/kgBB
Slightly toxic	≤ 15 g/kgBB
Non toxic	> 15 g/kgBB

Histopatology Analysis

Histopatology interpretation shows that there is damage in liver, kidney and lung on each treatment groups and control group. Liver and kidney histopatology analysis can be performed with random observation in some field of view.

The damage level of liver is increased from group 1, group 2, group 3, group 4 to group 5 respectively. It shows that the EEM dose exhalation can increase toxicity on mice liver.

Histopatology analysis shows the necrosis on kidney according to proximal tubule constriction around glomerular. Control group shows 5% damage and the percent damage increases regarding to the dose level. The damage level of kidney is increased from group 1, group 2, group 3, group 4 to group 5 respectively. Group 5 shows 20% damage on kidney and gives the most severe damage compare with the other groups. It means that the exhalation of EEM dose level can increase toxicity in mice kidney.

The result shows that EEM administration to mices in 14 days of observation period causes the liver and kidney damage on mice (*Musmusculus* Linn). EEM gives the toxic activity in dose dependent manner. The necrosis of liver was predicted caused by the active compound of EEM. Mimba herbs contain several active compound such as azadirachtin, salanin, meliantrirole, nimbin, nimbolidedangedunin (Biswas, et al, 2002).

CONCLUSION

EEM can treat tuberculosis marmot infected with *Myobacterium tuberculosis* H37RV at the certain dose and is classified in slightly toxic.

AKNOWLEDGEMENT

We express our gratitude to DP2M Dirjen DIKTI, Chief of Balai Pengobatan Penyakit Paru

Sumatera Utara, Nur Sabrina and Bagekin, and Faculty of Pharmacy UTND Medan.

REFERENCES

- Almas, K., 1999, The Antimicrobial Effects of extracts of *Azadirachta indica* (Neem) and *Salvadora persica* (Arak) Chewing Sticks, *Indian J. Dent. Res.*, **10**(1), 23-6.
- Ambarwati, 2007, The Effectiveness of Antibacteria Substances from Neem Seeds (*Azadirachta Indica*) to Impede the Growth of *Salmonella Thyposa* and *Staphylococcus Aureus*, *Biodiversitas*, **8**(3), 320-325.
- Anonim, 2000, *Pedoman Pelaksanaan Uji Klinik Obat Tradisional*, Departemen Kesehatan RI, Jakarta.
- Biswas, K., CHattopadhyay, I., Bnerjee, R.K. and Bandyopadhyay, U. 2002, Biological Activities and Medicinal Properties of Neem (*Azadirachta Indica*), *Curr. Scie.*, **82**(11), 1336-1345.
- Dalimatha, S., 2000, *Atlas Tanaman Obat Indonesia*, Jakarta: Trubus Agriwidya.
- Depkes RI, 1995, *Materia Medika Indonesia, Jilid IV*, Jakarta: Departemen Kesehatan Republik Indonesia.
- Depkes RI, 2000, *Parameter Standar Umum Ekstrak Tumbuhan Obat*, Jakarta: Departemen Kesehatan Republik Indonesia.
- Fatimah, 2012, *Uji Aktivitas Antituberculosis Ekstrak Etanol Kulit Batang Mimba (Azadirachta indica Juss.) terhadap Mycobacterium tuberculosis*, Universitas Tjut Nyak Dhien Medan, Sumatera Utara.
- Ganiswara, 1995, *Farmakologi dan terapi*, Jakarta: Gaya Baru, 602-603.
- Wattimena, J.R., 1991, *Farmakodinamik dan Terapi Antibiotik*, Yogyakarta: GadjahMada University Press.